Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did I pick the right stock with Ariad? If what Harvey said is true, could we have a repeat? Dreamer?
http://finance.yahoo.com/q/bc?s=REGN&t=5y&l=on&z=l&q=l&c=
Yeah, Harvey mentioning that Ariad will mature to the likes of Celgene probably has a few from Ariad staying awake tonight... Wow, a 31 Billion market cap..
Let me put it this way.. Where do you think the technicals were when I bought most all my Ariad from $2.70 to $4.40? 'Nuff said.. I'm really not too concerned what your friends at Goldman or B of A do, to be honest with you..
I'll take the high potential of two new approved biotech compounds any day over a bunch of lines and graphs..
2damoon1, I can't tell you how much I appreciate you stepping back into the fold as we enter a very critical, exciting time for Ariad. Who knows.. iHub moderator czar, to aspiring political candidate!
Share price? It's funny in that I had to laugh when I saw the posts on $45 share prices awhile back. However, with the glimmer of information that we now know on the efficacy of '113, it has moved Ariad to a whole new level, imho. I mean when I read that description from that pt, I had to sit down. It stunned me. That anchored my conviction. This is a whole new chapter. And, I believe it will be moving rather quickly..
Looks like we fall in the 15's with the way the futures are looking..
I'm more worried about patient blogs here being picked up by the Yahoo Ariad message board crowd, which if you have visited there, appear to be a bunch of third world derlicks. They are the type of individuals that potentially would pester the patients, and then the flow of information will be less forthcoming.
All refugees that moved here from there are naturally excluded..
Civic, what did you mean by this?
BTH,isn't it a stretch to consider the compound '113, that just left the mouse model in the fall last year, to be a mulitbillion business in the future? I mean is there that much circumstantial evidence to reach that conclusion?
I expect the color of Harvey's thoughts on the Q1 CC next week will be more revealing than ASCO.
Rida approval is less than 10%, and it doesn't matter.
binchey, if you listen to the Ariad CC next week, you will learn something on AP26113..
I can't take all of them at once, only a few at a time as they appear in the messages. Make Ariad rise higher it seems..
Time for a couple of lovely ladies!!
Chart model for Ariad's future:
http://finance.yahoo.com/q/bc?s=PCYC+Basic+Chart&t=5y
You may be right.. If Harvey can just give us a glimmer of positive AP26113 data, that is all she wrote, and we will have lift off.. But, the guy buying those options yesterday knew that...
This is a prudent way to use options with Ariad:
http://www.optionmonster.com/news/article.php?page=bulls_take_large_dose_of_ariad_pharma_68567.html
The 8K is filed on the same day, after the announcement, not before.
Harvey doesn't have to say a word initally. The aquiring company will bang the drums and toot their horns to let the world know that they want to aquire the company in an effort to help force their plan through public opinion..
2damoon, you completely missed the point. It has nothing to do with the charts. Think about it..
IIIverson, don't you think you have went over the edge with this stuff? I realize that you have a free hall pass from the Moderators, but really..............
SAC Capital's Steve Cohen means business. It is always refreshing when a hedge fund buys your stock at the top of the range:
http://www.marketfolly.com/2012/04/sac-capital-buys-more-ariad.html
This reminds me of the game, "crush that dwarf"
Ariad has no "rights" to Rida.. Only milestones and royalties..
Can anyone comment on these Rida poster sessions at ASCO? ...And, why Ariad when it should be Merck?
IIIverson, nice work, but just to keep it accurate:
Matthew 21:21-22
21 Jesus replied, “Truly I tell you, if you have faith and do not doubt, not only can you do what was done to the fig tree, but also you can say to this mountain, ‘Go, throw yourself into the sea,’ and it will be done. 22 If you believe, you will receive whatever you ask for in prayer.”
Amen!
Great video on where we are with Ariad, technically.. (a student of IIIverson no doubt):
http://www.advicetrade.com/chartsoftheday/BA-GNC-HOG-ONXX-Among-Charts-to-Watch-20120425913.html
IIIverson, I will never doubt your "Wizzard of Odd", all knowing, all inclusive, never divergent, black magic, atomic particle accelerator T.A. machine. It works! That is, until the next time....
A little short covering today?
http://shortanalytics.com/getshortchart.php?tsymbol=aria
Nawh, it wouldn't be NVS.. Merck needs this more than anyone..
I always wanted to say, "Ariad is on fire!!" Thanks for reading.. (not on the highest volume, however)
allopurinol works like a charm, as been around for 40 years, and costs $12 for a 90 day supply..
I know it's way too early for these indications, but don't forget these targets for added value 18 to 24 months down the road:
Ponatinib potently inhibited the activity of these kinases and maintained potent activity against gatekeeper variants that have been shown to cause resistance to other tyrosine kinase inhibitors in acute myeloid leukemia, medullary thyroid cancer, gastrointestinal stromal tumor (GIST) and rare forms of leukemia driven by these tyrosine kinases.
“Ponatinib was designed to block the abnormal tyrosine kinase, BCR-ABL, which drives CML and Ph+ALL,” said Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer of ARIAD. “The structural design feature that allows ponatinib to evade the BCR-ABL T315I gatekeeper mutation also enables the molecule to overcome analogous mutations in its other kinase targets. We are actively working with academic collaborators to set up clinical trials aimed at determining the potential role of ponatinib in these additional forms of drug-resistant cancer.”
If we could clear $15.50, I would be absolutely thrilled..
That $14.10 print a few days ago took the wind out of my sail..
Gambling will save Spain.. Now that is an interesting thought..
All I'm saying is the green chart at the top of this page scares me right now, that's all..
It's funny..all these chartists claim there is support in them thair hills, and if they would just step back and look at the chart, it told them to sell $2 ago, and they just didn't see it..